A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
NCT01201915
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
74
Enrollment
INDUSTRY
Sponsor class
Conditions
Basal Cell Carcinoma
Interventions
DRUG:
Vismodegib
Sponsor
Genentech, Inc.